A Study of LY3537031 in Overweight, Obese, and Healthy Participants

StatusActive, Not Recruiting
PhasePhase 1
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 3 months later Jul 2026 → Nov 2026
See other at-risk trials from Eli Lilly

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary and study completion pushed from Jul 2026 to Nov 2026
    • Eligibility criteria expanded, about 10 words
  2. Secondary endpoints: details revised at 11 of 11 entries
    • Study arms: 7 to 8
    • Eligibility criteria expanded, about 1 word
    v18
  3. Trial status: Recruiting to Active, Not Recruiting
    • Site details revised at 5 of 5 sites
    v17
  4. Re-verified, no change to tracked fieldsv16
  5. Site details revised at 1 of 5 sitesv15
Show 13 earlier versionsHide 13 earlier versions
  1. Site details revised at 1 of 5 sitesv14
  2. Enrollment target: 230 to 302
    • Eligibility criteria expanded, about 9 words
    • Study arms: 6 to 7
    v13
  3. 2 versions Re-verified since May 25, 2025, no change to tracked fieldsv11-v12
  4. Secondary endpoints: details revised at 11 of 11 entriesv10
  5. Re-verified, no change to tracked fieldsv9
  6. Primary and study completion dates: Jul 2025 to Jul 2026
    • Site details revised at 4 of 5 sites
    v8
  7. Site contacts updated at 1 of 5 sitesv7
  8. Site details revised at 5 of 5 sitesv6
  9. Site contacts updated at 5 of 5 sites
    • Eligibility criteria shortened, about 2 words
    v5
  10. Re-verified, no change to tracked fieldsv4
  11. Study Status, Referencesv3
  12. Study sites: 1 to 5v2
  1. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Eli Lilly
363 trials monitored
See 16 trials at risk
Obesity
3,888 trials monitored
See 157 trials at risk
This is a 4-part study that includes a Part A, Part B, Part C, and Part D. Parts A and D will study the safety and tolerability of the study drug known as LY3537031 in participants who are overweight and obese. Part B and Part C will study the safety and tolerability of LY3537031 in healthy participants. Part C will contain only Japanese and Chinese healthy participants. Blood tests will be performed to check how much LY3537031 gets into the bloodstream and how long it takes the body to eliminate it. Body weight will be measured. The study will last approximately 49 weeks excluding a screening period.
Trial Details
NCT Number NCT06606106
Lead Sponsor Eli Lilly and Company
Conditions
(from sponsor)		 Overweight, Obesity
Related terms Obesity, Overweight
Enrollment 302 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov